title: Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA. Electronic address: jallen@foundationmedicine.com.
authors.forename: Justin M
authors.initials: JM
authors.lastname: Allen
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Alexa B
authors.initials: AB
authors.lastname: Schrock
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Rachel L
authors.initials: RL
authors.lastname: Erlich
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Vincent A
authors.initials: VA
authors.lastname: Miller
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Stephens
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Department of Medicine, Division of Hematology-Oncology, University of California, Irvine, School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA.
authors.forename: Sai-Hong Ignatius
authors.initials: SI
authors.lastname: Ou
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Siraj M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA.
authors.forename: Davood
authors.initials: D
authors.lastname: Vafai
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics*; D000077716:Afatinib; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung; D000068818:Cetuximab / Q000627:therapeutic use; D000074141:Circulating Tumor DNA / Q000032:analysis*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling; D016678:Genome / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D008869:Microtubule-Associated Proteins / Q000235:genetics*; D009154:Mutation / Q000235:genetics; D009362:Neoplasm Metastasis; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011799:Quinazolines / Q000627:therapeutic use; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics*; D012008:Recurrence
chemical_list: D000074141:Circulating Tumor DNA; D008869:Microtubule-Associated Proteins; D015514:Oncogene Proteins, Fusion; D011799:Quinazolines; C120551:TACC3 protein, human; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3; D000068818:Cetuximab
keywords: Acquired resistance; EGFR mutation; FGFR3 fusion; Non–small-cell lung cancer; ctDNA